Noile-Immune Biotech Inc. [4893.T]
TOKYO, Apr 15 (Pulse News Wire) – Noile-Immune Biotech Inc. (4893.T) resolved today to issue restricted shares as compensation to its directors and external directors.
The issuance, scheduled for May 14, 2026, involves issuing ordinary shares worth ¥150 per share, totaling ¥14.6 million. The shares will be allocated to five designated recipients, comprising three internal directors and two external directors. In total, the company will allocate 97,353 ordinary shares. The cash compensation amounting to ¥14.6 million will be converted into these shares through a direct contribution method. The allocation amount for each recipient is determined based on their contributions and various factors within the company.
The restricted period for these shares begins on May 14, 2026, and ends upon the director's resignation or retirement from any position within the company. During this period, the recipients cannot transfer, pledge, or dispose of the shares in any way. Should a director resign or retire before the end of the fiscal year without valid reasons, the company reserves the right to acquire the sharesly. Additionally, the dilution impact of this issuance is considered reasonable, affecting approximately 0.22% of the outstanding shares as of December 31, 2025, which totaled 43,301,765 shares. The company believes this aligns with the objectives of enhancing shareholder value and promoting greater alignment among management and shareholders.
🟢 Confidence: High AI-translated content.